This pharmaceutical company is expected to post quarterly earnings of $1.11 per share in its upcoming report, which represents a year-over-year change of -15.3%. Revenues are expected to be $1.62 billion, up 1% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.96% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. ...